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Abstract 
Klinefelter’s  syndrome  is  characterized  by
abnormal karyotype 47, XXY and a phenotype
associated  with  hypogonadism  and  gyneco-
mastia.  Often  the  disease  can  be  diagnosed
accidentally,  when  carrying  out  cytogenetic
analysis in cases of a malignant blood disease.
We present the clinical case of a patient diag-
nosed with acute myelomonoblastic leukemia-
M4 Eo (AML- M4), where by means of classic
cytogenetics  a  karyotype  was  found  corre-
sponding  to  Klinefelter’s  syndrome.  Three
induction  courses  of  polychemotherapy  wer-
made, which led to remission of the disease,
documented both flowcytometrically and cyto-
genetically.
Introduction
Klinefelter’s syndrome was first described in
1942 as an endocrine disorder characterized by
gynecomastia, hypogonadism and higher lev-
els of follicle-stimulating hormone. It is usual-
ly associated with 47 chromosomes, including
two  X and  one  Y  (47,XXY).1,2 Infertility  and
gynecomastia are the two most common symp-
toms  pointing  to  the  diagnosis.3 Mamunes
describes a patient with Klinefelter’s syndrome
and acute leukemia for the first time in 1961.2
Consequently some medical manuals and clin-
ical reports suggest that there is an increased
risk  of  leukemia  and  lymphoma  in  patients
with Klinefelter’s syndrome,4,5 but such a risk
has never been proved. In cytogenetic tests of
bone marrow of 5366 patients with malignant
hematological diseases, only six of the patients
had  a  karyotype  compatible  with  Klinefelter.
Out of these six patients three had myelodys-
plastic syndrome, two had non- Hodgkin’s lym-
phoma and one was with acute myeloblastic
leukemia. The fact that a cytogenetic analysis
is  routinely  carried  out  in  patients  with
leukemia and lymphoma by means of which
constitutional abnormalities of the karyotype
may be detected and should not be related with
a connection between Kline felter’s syndrome
and  malignant  hematologic  diseases.6
According  to  one  retrospective  study  in
Denmark  in  696  patients  with  Klinefelter’s
syndrome not a single case of leukemia or lym-
phoma was established.7
Clinical Presentation
KEK- 34-year-old man diagnosed with acute
myelomonoblastic leukemia (AML- M4), dete-
rmined for the first time during his stay in the
clinic in July 2006, when he entered with com-
plaints of weakness, fatigue at normal physical
exercise and fever to 38°C. The physical exam-
ination did not show any pathological abnor-
malities.  The  conducted  laboratory  tests  –
complete  blood  count  and  differential  count
showed: Hb 76.0 g/dL, RBC 2,2ﾥ1012/L, PLT 46
ﾥ109/L,  WBC  3,5ﾥ109/L,  band  2%,  segmented
neutrophils 3%, eosinophils 1%, lymphocytes
76%,  monoblasts  18%.  The  flow  cytometric
analysis of bone marrow during diagnostica-
tion  showed:  myeloblasts  expressing:  CD13,
CD33,  CD34,  CD117  and  monoblasts  with
immuno-phenotype  CD11b,  CD11c,  CD13,
CD14, CD33, CD64, HLA- DR. Conclusion: the
described flow cytometric finding is character-
istic  oo  AML  -M4  (Figure  1).  Cytogenetic
analysis was performed of 18 metaphase plates
of  bone  marrow  which  showed:  46,  XХ,(7)  -
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Figure  1.  Flow  cytometric
analysis  of  bone  marrow.
Flow  cytometric  diagnosis
of AML M4 was established.
(A) CD45/Side light scatter
(SSC) dot plot picture with
two  gates  set  around
myeloblast cells and mono  -
blast cells. (B) Fluore  scence
(Fl) 1/Fl2 dot plot presenta-
tion  of  myeloblast  cells
(right  dot  plots  -  CD34+/
CD33+/-/CD13+/  CD11b-
/CD64-/HLADR-)  and
monoblast  cells  (left  dot
plots  -  CD34-/CD33+/
CD13+/CD11b+/CD64+/H
LADR+). [Hematology Reports 2010; 2:e11]
(q32;q36),t(8;21)(q22;q22),del(7)(q32;q36).  A
complex aberrant karyotype was found and not
conforming to the sex, which led to a cytoge-
netic analysis of peripheral blood lymphocyte
culture  stimulated  with  phytochemaglutinin,
due to which the karyotype 47, XXY was found,
corresponding to Klinefelter’s syndrome. Two
induction courses were carried out including:
epirubicin  and  cytarabine  at  conventional
doses and mitoxantron with cytarabine, which
resulted in reduction of the blast population in
the  bone  marrow.  Hematological  remission
with complete cytogenetic response (CCyR) of
the disease was achieved after the third induc-
tion course containing mitoxantron, eteposide
and cytarabine, documented by means of flow
cytometric and cytogenetic analysis in October
2006 (Figure 2). Consolidation was carried out
with mitoxantrone and cytarabine, followed by
maintainance  therapy  with  mercaptopurine
and  methotrexate,  and  monthly  reinduction
courses  (epirubicin  and  cytarabine,  mitox-
antrone and cytarabine – in turns) thro- ugh-
out the first year, every two months throughout
the  second  year  and  every  three  months
throughout the third year. At the end of the
second year flow cytometric, cytogenetic and
molecular analysis (Figure 3) was carried out
once again of bone marrow, which con- firmed
the achieved remission. 
PCR assay for AML1-ETO fusion
trasnscripts 
The presence of AML1-ETO rearrangement
was  determined  by  nested  primers  Reverse
Transcription  Polymerase  Chain  Reaction
(RT-PCR). Total RNA was extracted from bone
marrow  cells  using  TRizol  Reagent
(Invitrogen BRL) according to the manufac-
turer's  instructions.  Complementary  DNA
(cDNA) synthesis and amplification was done
according  to  the  protocol,  recommended  by
the European BIOMED 1 Concerted Action for
standartization  of  MRD  studies  in  acute
leukaemia.8 In  addition,  an  amplification  of
beta-Actin mRNA with primers 5’-GGCATCGT-
GATGGACTCCG-3’  and  5’-GCTGGAAGGTG-
GACAGCGA-3’was performed as a marker for
RNA integrity and efficiency of copy DNA syn-
thesis. Amplification products were run in a
2% agarose gel (Invitrogene BRL) after stain-
ing  with  ethidium  bromide,  visualized  after
UV  irradiation  and  photographed.  Kasumi-1
cell line was used as a positive control and
RNA from healthy donors as a negative con-
trol. In addition, RNA from each sample using
the  same  RT-PCR  conditions  and  reagents
omitting the reverse transcriptase, and a mix-
ture, containing all the reagents except the
nucleic acids have also been used as negative
controls 
Discussion
The  described  clinical  case  is  of  interest
due to the fact that to the moment of manifes-
tation of the acute leukemia, Klinefelter’s syn-
drome was not diagnosed. For the period from
2003 to 2007, 72 men, (average age 59,78),
entered  the  hematological  clinic  in  Pleven
with  newly  diagnosed  acute  leukemia,
Klinefelter’s syndrome was found in only one
of them, who also had a second chromosomal
abnormality  t(8;21)(q22;q22).  According  to
some  authors  two  mutational  events  are
required for the development of cancer: the
first step may be a constitutional event and
the second an acquired genetic mutation.9 It is
an  open  question  whether  the  presence  of
three sex chromosomes is an event that leads
to  chromosomal  instability.  Some  of  the
national  and  international  cooperative
research  groups  (Medical  Research  Council
group; CALGB and GIMEMA/AML10) con- sider
that complementary aberration, even the com-
plex karyotype, do not influence significantly
the  prognosis  in  cases  of  favorable  aberra-
tions. Other research groups ( SWOG/ ECOG,
HOVON/  SAKK)  have  found  reliable  differ-
ences in the prognosis of patients with “good”
features in the karyotype with or without com-
plex karyotype.10
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Figure 2. The karyotype corresponds to Klinefelter`s syndrome. No structural chromo-
somes were detected: complete cytogenetic response regarding t(8;21)(q22;q22). Routine
cytogenetic analysis was performed on metaphase chromosomes from bone marrow sam-
ples  using  a  direct  method  and  after  short-term  24  hours  or  48  hours  culturing.
Metaphases were analyzed using GTG differentially stained chromosomes at a discrimina-
tory level of 300-400 bands per haploid count. Karyotypic findings were interpreted and
described according to the International System for Human Cytogenetic Nomenclature
(ISCN, 2009).8
Figure 3. Detection of residual AML1-ETO
transcripts by Nested Primers (NP) Reverse
Transcription Polymerase Chain Reaction
(RT-PCR).(A) Control amplification of ʲ-
Actin cDNA as a marker for RNA integrity
and efficiency of copy DNA synthesis. (B)
First  round  PCR  for  AML1-ETO  tran-
scripts – absence of product of amplifica-
tion.  (C)  Second  round  PCR  for  AML1-
ETO transcripts – weak positive reaction
corresponding to relatively low number of
AML1-ETO  transcripts.  PCR  assay  for
AML1-ETO fusion trasnscripts. [page 56] [Hematology Reports 2010; 2:e11]
References
1. Swerdlow  AJ,  Schoemaker  MJ,  Higgins
CD.  Cancer  incidence  and  mortality  in
men with Klinefelter syndrome: a cohort
study.  Journal  of  the  National  Cancer
Institute 2005;97:1204-10.
2. Kumar  DM,  Menke  GW,  Dewald  G.
Agnogenic myeloid metaplasia associated
with Klinefelter syndrome: a case report.
Ann Hematol 2002;81:215-8.
3. Catovic  A.  Phenotype  manifestation  of
polysomy X at males. Bosnian journal of
basic medical sciences. 1998;2:1512-8.
4. Provan D, Singer Ch, Baglin T, Lilleyman J.
Acute  lymphoblastic  leukemia.  Oxford
Handbook  of  clinical  haematology
2004;158-63.
5. Shaw P, Eden OB, Grace E, Ellis PM. Acute
Lymphoblastic Leukemia and Klinefelter's
Syndrome Pediatr Hematol Oncol 1992;9:
81-5.
6. Eberl  MM,  Baer  MR,  Martin  C.
Unsuspected  Klinefelter  syndrome  diag-
nosed during oncologic evaluation: a Case
Series. JABFP 2005;18:132-9
7. Hasle  H,  Mellemgaard  A,  Nielsen  J,
Hansen  J.  Cancer  incidence  in  men
withKlinefelter  syndrome.  Br  J  Cancer
1995; 71:416-20.
8. van Dongen JJ, Macintyre EA, Gabert JA, et
al. Standardized RT-PCR analysis of fusion
gene transcripts from chromosome aber-
rations in acute leukemia for detection of
minimal  residual  disease.  Report  of  the
BIOMED-1 Concerted Action: investigation
of  minimal  residual  disease  in  acute
leukemia. Leukemia 1999;13:1901-28.
9. Welborn  J.  Constitutional  chromosome
aberrations  as  pathogenetic  events  in
hematologic malignancies. Cancer Genet
Cytogenet 2004;149:137-53.
10. Grimwade D, Hills R. Independent pronos-
tic factors for AML outcome. Hematology
Am Soc Educ Program 2009;385-95 
Case Report